HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Guanze Intelligent Medical Information Industry - Advantages in Shandong Cannot Hide Worries

China Healthcare Weekly (Apr.1)- Lower Budget of Public Hospitals, IPO Environment, Impatient Market

Pre-IPO Betters Medical Investment Holdings - The Industry, the Business and the Concerns

China Healthcare Weekly (Mar.25)- Viable Business Model for Pharma, CXO for CGT, China Sleep Economy

The Impact of HFCAA on China ADR (China Healthcare Companies)

Presentation for Impact of Russia/Ukraine War on Asian Markets-Tiantan Biological Products(600161CH)

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Hutchison China MediTech Ltd / Equity Bottom-Up

<ul>
<li>For the three commercialized products (fruquintinib, surufatinib and savolitinib), they are facing challenges from different aspects. </li>
<li>The lack of blockbuster products and promising targets indicates that Hutchmed's current pipeline does not have core competitiveness, which means Hutchmed's position in the industry is not in first echelon.</li>
<li>In fact, Li Ka-shing's positioning and original intention for Hutchmed is not on innovative drugs. So, big but not strong has always been the pain point of the Company.</li>
</ul>


For the three commercialized products (fruquintinib, surufatinib and savolitinib), they are facing challenges from different aspects. 
The lack of blockbuster products and promising targets indicates that Hutchmed's current pipeline does not have core competitiveness, which means Hutchmed's position in the industry is not in first echelon.
In fact, Li Ka-shing's positioning and original intention for Hutchmed is not on innovative drugs. So, big but not strong has always been the pain point of the Company.


Shanghai Fosun Pharmaceutical (Group) (2196 HK)

Hutchmed China Ltd (13.HK/HCM.US) - Big but Not Strong